• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Law Offices of Frank R. Cruz Encourages Baxter International, Inc. (BAX) Shareholders to Inquire About Securities Fraud Class Action

By: Law Offices of Frank R. Cruz via Business Wire
October 28, 2025 at 12:06 PM EDT

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”). Baxter investors have until December 15, 2025 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR BAXTER INTERNATIONAL, INC. (BAX) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On April 7, 2025, a Missouri news outlet reported serious safety issues relating to inaccurate infusion rates with Baxter’s Novum IQ Large Volume Pump (“Novum LVP”), a device used for the controlled delivery of intravenous fluids, based on information from a whistleblower at a local hospital system. The whistleblower claimed that “patients should not be being treated with these pumps. These pumps are not safe.” The report led to the hospital system’s removal of all Novum LVPs.

Then, on April 24, 2025, Baxter sent warning letters to customers regarding a potential underinfusion risk associated with the Novum LVP, disclosing only one serious injury linked to this issue. On July 14, 2025, the Company issued a second warning letter repeating the underinfusion risk along with an additional overinfusion risk, revealing that it had received 79 reports of serious injury and two reports of patient deaths related to the Novum LVP. The FDA subsequently classified these issues as a Class I recall, its most serious designation, reflecting a risk of severe injury or death.

Then, on July 31, 2025, Baxter announced that it was “voluntarily and temporarily [pausing] shipments and planned installations of the Novum LVP” and that the Company was “unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs.”

On this news, Baxter’s stock price fell $6.24, or 22.4%, to close at $21.61 per share on July 31, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Baxter common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz

2121 Avenue of the Stars, Suite 800

Telephone: 310-914-5007

Email: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028400633/en/

Law Offices of Frank R. Cruz Encourages Baxter International, Inc. (BAX) Shareholders To Inquire About Securities Fraud Class Action

Contacts

Law Offices of Frank R. Cruz

2121 Avenue of the Stars, Suite 800

Telephone: 310-914-5007

Email: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com

More News

View More
Q3 Telecom Wars: How AT&T, TMUS and VZ Stack Up After the Results
Today 10:14 EST
Via MarketBeat
Tickers FYBR T TMUS VZ
Boeing Closes in on Airbus With Best Delivery Quarter Since 2018
Today 9:09 EST
Via MarketBeat
Tickers BA EADSY
Put It on My Card: Why Luxury Brands and Payments Firms Pair Well
Today 8:11 EST
Via MarketBeat
Tickers MA RACE
3 Safe and Steady Stocks for Any Market
Today 7:03 EST
Via MarketBeat
Tickers DOC KMB KO MSFT NVDA
Is Lemonade Stock Set for a Big Squeeze After Earnings?
November 02, 2025
Via MarketBeat
Tickers LMND

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.33
+11.11 (4.55%)
AAPL  268.32
-2.05 (-0.76%)
AMD  255.91
-0.21 (-0.08%)
BAC  52.82
-0.63 (-1.18%)
GOOG  282.84
+1.02 (0.36%)
META  652.38
+4.03 (0.62%)
MSFT  520.38
+2.57 (0.50%)
NVDA  208.25
+5.76 (2.84%)
ORCL  258.12
-4.50 (-1.71%)
TSLA  469.38
+12.82 (2.81%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap